Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Intangibles (2019 - 2025)

IGC Pharma (IGC) has disclosed Change in Intangibles for 7 consecutive years, with $297000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Intangibles rose 471.15% to $297000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $636000.0, a 34.18% increase, with the full-year FY2025 number at $370000.0, down 1.86% from a year prior.
  • Change in Intangibles was $297000.0 for Q3 2025 at IGC Pharma, up from $114000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $498000.0 in Q1 2022 to a low of $2000.0 in Q2 2021.
  • A 5-year average of $106947.4 and a median of $52000.0 in 2024 define the central range for Change in Intangibles.
  • Peak YoY movement for Change in Intangibles: crashed 92.31% in 2021, then soared 1560.0% in 2022.
  • IGC Pharma's Change in Intangibles stood at $22000.0 in 2021, then surged by 281.82% to $84000.0 in 2022, then crashed by 77.38% to $19000.0 in 2023, then surged by 305.26% to $77000.0 in 2024, then skyrocketed by 285.71% to $297000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Intangibles are $297000.0 (Q3 2025), $114000.0 (Q2 2025), and $148000.0 (Q1 2025).